论文部分内容阅读
目的:观察脐带血血清体外培养体系培养的人骨髓间充质干细胞对干细胞移植病人造血重建的影响及不良反应。方法:用10%脐带血血清体外培养体系培养的人骨髓间充质干细胞联合自体外周血干细胞移植治疗3例恶性淋巴瘤患者,计数BM-MSC的数目,观察其造血重建时间、不良反应。结果:采用10%脐带血血清培养体系培养BM-MSC,回输时达到2.82-3.96×106/kg,3例患者中性粒细胞>0.1×109/L的时间为移植后第9-12天,血小板>20×109/L的时间为移植后第9-15天,无明显不良反应。结论:10%脐带血血清培养体系是一种基于临床移植需要的分离、培养人BM-MSC的方法,此法培养的BM-MSC联合APBSC移植治疗恶性淋巴瘤患者,加速了造血重建,未见明显不良反应,具有临床应用价值。
Objective: To observe the effect and adverse reactions of human bone marrow mesenchymal stem cells cultured by cord blood serum in vitro on hematopoietic reconstitution of stem cell transplantation patients. Methods: Three cases of malignant lymphoma were treated with human bone marrow mesenchymal stem cells and autologous peripheral blood stem cells cultured in 10% cord blood serum culture system. The number of BM-MSCs was counted and the hematopoietic reconstitution time and adverse reactions were observed. Results: BM-MSCs were cultured in 10% cord blood serum culture system and reached 2.82-3.96 × 106 / kg at the time of reinfusion. The time of neutrophil> 0.1 × 109 / L in 3 patients was 9-12 days after transplantation , Platelets> 20 × 109 / L for the first 9-15 days after transplantation, no significant adverse reactions. CONCLUSION: The 10% cord blood serum culture system is a method of isolation and culture of human BM-MSC based on clinical transplantation. BM-MSC combined with APBSC transplantation in patients with malignant lymphoma can accelerate the hematopoietic reconstitution. Obvious adverse reactions, with clinical value.